SNPX / Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the more_horizontal

Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work more_horizontal

NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal

NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company more_horizontal

NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutic more_horizontal

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p more_horizontal